Supriya Lifescience Limited is an Indian pharmaceutical company. It was established in 1987 and is headquartered in Mumbai. It is a prominent global producer of active pharmaceutical ingredients (APIs).
In API manufacturing, the company specialises in products across diverse therapeutic segments such as anti-histamines, anti-allergics, vitamins, anaesthetics and anti-asthmatics.
The company has a worldwide presence, reaching 86 countries. It’s domestic operations are spread across 12 states in India. Its product portfolio of active pharmaceutical ingredients includes more than 38 products.
The market capitalisation of Supriya Lifescience Limited stood at over ₹2,400 crore as of January 19, 2024. Supriya Lifescience share price has gained 42% in the last three years.
Supriya Lifescience Limited business operations
Supriya Lifescience Limited is a major supplier of active pharmaceutical ingredients (APIs) globally. It ensures efficient procurement from both Indian and global sources including China, South Korea and Belgium.
The company serves many well-known global pharmaceutical firms. A few of them are Syntec Do Brasil LTDA, American International Chemical Inc, AT Planejamento E Desenvolvimento De Negocios Ltd, Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd, among others. Approximately 45% of the company's revenue comes from its top 10 customers.
In FY23, the company generated 20% of its revenues domestically and 80% from exports. Asia and Europe contributed the most to the company's revenue, followed by Latin America and North America.
The company operates a backwards-integrated production facility located in Lote, Parshuram in Maharashtra. It spans 23,806 square meters and is divided into four blocks based on therapy. The facility includes a reactor with a capacity of 547 KL. It has approvals from various regulatory bodies including USFDA, EDQM and EUGMP. The company has also received marketing auithorisations from AIFA in Italy, TGA in Australia, BfArM in Germany, KFDA in Korea, PMDA in Japan, SFDA in China and COFEPRIS in Mexico.
The facility features designated sections for warehouse, production, finished products and dedicated blocks for different therapeutic segments. As part of the company's capacity expansion plan, the facility is projected to reach approximately 1000+ KL by 2024. The facility in Lote also houses a DSIR-approved R&D facility. The company has plans to expand its product segments within its portfolio and is in the process of establishing two new R&D centres.
In FY23, Supriya Lifescience Limited expanded its manufacturing capabilities by incorporating four new laboratories into its existing facility at Lote. Construction is also underway for a manufacturing facility with a capacity of 330 KL. It is anticipated to become operational by February 2024.
By the end of FY23, the company had submitted 15 active Drug Master Files (DMFs) to the USFDA. It also submitted nine active Certificates of Suitability (CEPs) to the European Directorate for the Quality of Medicines and Healthcare for its API products.
Supriya Lifescience Financial Highlights
- Revenue: Supriya Lifescience reported revenue of ₹839.37 crore in FY26 vs ₹706.31 crore in FY25. It showed an increase of 18.84% on a yearly basis.
- Operating Profit: Supriya Lifescience reported an operating profit of ₹274.78 crore in FY26 vs ₹248.48 crore in FY25. It showed an increase of 10.58% on a year-on-year basis.
- Net Profit: Supriya Lifescience reported a net profit of ₹209.12 crore in FY26 vs ₹187.96 crore in FY25. It showed an increase of 11.26% on a yearly basis.
Supriya Lifescience Quarterly Result Highlights
- Supriya Lifescience reported revenue of ₹192.40 crore in Jun 2026, compared with ₹280.01 crore in Mar 2026, representing a decrease of 31.29% on a quarter-on-quarter (QoQ) basis.
- Supriya Lifescience reported an operating profit of ₹40.79 crore in Jun 2026, compared with ₹92.13 crore in Mar 2026, representing a decrease of 55.73% on a quarter-on-quarter (QoQ) basis.
- Supriya Lifescience reported a profit of ₹24.04 crore in Jun 2026, compared with ₹74.23 crore in Mar 2026, reflecting a decrease of 67.61% on a QoQ basis.
- The earnings per share (EPS) of Supriya Lifescience stood at ₹25.98 during Jun 2026.
Data Source: BSE, Company announcements
Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.
